UniQure (NASDAQ:QURE) is a biotechnology company focused on developing gene therapies for patients with severe genetic diseases. The company is known for its innovative approach to treating neurological conditions. However, it faces competition from other biotech firms in the gene therapy space, which is a rapidly evolving sector.
On March 2, 2026, Luca Issi from RBC Capital set a price target of $11 for QURE. At that time, the stock was priced at $10.25, indicating a potential upside of approximately 7.32%. However, recent developments have impacted the stock's performance. The U.S. Food and Drug Administration (FDA) informed UniQure that data from its early-to-mid stage trial is insufficient for a marketing application for its gene therapy targeting brain disorders.
This FDA decision is a significant setback for UniQure, affecting its stock price. Currently, QURE is priced at $10.50, reflecting a decrease of 32.82% with a change of $5.13. The stock has fluctuated between $8.96 and $11.08 yesterday, showing volatility in response to the news. Over the past year, QURE has seen a high of $71.50 and a low of $7.76, indicating a challenging period for the company.
UniQure's market capitalization is approximately $646.84 million, highlighting its position in the biotech industry. The trading volume for the day is 16,764,186 shares, suggesting significant investor interest and activity. Despite the recent challenges, the company remains focused on advancing its therapeutic offerings in the field of neurological conditions.
